Early Data On Amgen’s AMG 133 Show Potential Durability, Dosing Advantage In Obesity

 
• By Alaric DeArment
  
Amgen announced data on AMG 133 in obesity • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D